PPARG and Alzheimer disease: Lipidomics and molecular interlinking analyses indicated that the main pharmacodynamic substance, CG, present in BYHWD might activate the PPARγ pathway to induce peroxisome proliferation and regulate lipid metabolism disorders in the AD mice brain, thereby achieving therapeutic effects against AD.